HLB Group to Hold Integrated IR Day on Oct. 15... "Share Mid- to Long-Term Growth Direction"

HLB Group will hold an "Integrated IR Day" on October 15 at 3 p.m. for institutional investors and analysts, with 10 listed affiliates taking part.

According to HLB Group on October 12, the event is intended to provide investors with a more in-depth explanation of the business performance and mid- to long-term growth strategies of key affiliates, and to deepen the capital market's understanding of the group's corporate value. In particular, executives will directly introduce each affiliate's key business operations and future plans, then hold Q&A sessions to address market questions about their business strategies and growth potential in concrete terms.

HLB will share the performance of Ripiktu, a new cholangiocarcinoma drug that recently received U.S. FDA approval, as well as updates on the combination therapy of rivoceranib and camrelizumab, a first-line liver cancer treatment for which it has completed resubmission of an application to the FDA. It will also explain its mid- to long-term growth direction as a global pharmaceutical and biotech company. Alongside its growth strategy for its existing semiconductor business, HLB Innovation will present the development status of next-generation CAR-T therapies by Verismo Therapeutics, synergies in the bio business with recently acquired HLB Cell, and its mid- to long-term growth strategy.

HLB Therapeutics will share updates on the U.S. Phase 3 trial of RGN-259, a treatment for neurotrophic keratitis (NK), and its future commercialization strategy. HLB Genex plans to present the growth potential of its specialty enzyme business for the semiconductor and food industries, along with its strategy to expand into new biomaterials. HLB Panagene plans to present its business expansion strategy based on its PNA-AOC drug platform and AI-powered spatial proteomics diagnostic technology.

"This IR Day is an opportunity to explain the business performance and future growth strategies of our key affiliates to investors," said Lim Changyoon, vice chairman of investment at HLB Group. "We will continue to strengthen our communication with the market and build the value of the group as a whole on the basis of results in our core businesses."

This content was produced with the assistance of AI translation services.